ARS Pharmaceuticals stockholders elect three Class I directors, ratify EY as auditor at 2024 annual meeting

ARS Pharmaceuticals, Inc.

Shareholders elected Rajeev Dadoo, Michael Kelly, and Pratik Shah as Class I directors for terms expiring at 2027 annual meeting.
Proposal to ratify Ernst & Young as independent auditor for FY 2024 passed with over 79.9M votes for, 0.03M against.
Total shares outstanding and entitled to vote were 96,894,394 as of record date April 24, 2024.
Broker non-votes were 7.6M to 7.8M on director elections, none on auditor ratification.
All proposals received significant majority votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.